title: An Integrative Approach to Biomarker Development in Psoriatic Arthritis.
abstract: The recent discovery that the interleukin 23/Th17 pathway is pivotal in the pathogenesis of psoriatic arthritis (PsA) creates new opportunities for the development of mechanistic biomarkers that will assist in the diagnosis and management of this disorder. While biomarkers are still in the discovery phase, new approaches including multiplex panels, fine sequencing of epigenetic and genetic data in non-coding regions of the human genome, and improved imaging modalities will likely foster the development of actionable biomarkers in PsA. In this report, I review the field of biomarkers, underscore the importance of an integrative approach that incorporates both descriptive and mechanistic biomarkers, and discuss the status of biomarker discovery in PsA.
authors.affiliation: From the Allergy, Immunology and Rheumatology Division, Center for Musculoskeletal Medicine, University of Rochester Medical Center, Rochester, New York, USA.C.T. Ritchlin, MD, MPH, Professor of Medicine, Chief, Allergy, Immunology and Rheumatology Division, Center for Musculoskeletal Medicine. christopher_ritchlin@urmc.rochester.edu.
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Ritchlin
mesh_terms: D015535:Arthritis, Psoriatic / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D015415:Biomarkers / Q000378:metabolism*; D018450:Disease Progression; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D023281:Genomics / Q000379:methods; D006801:Humans; D010641:Phenotype; D011237:Predictive Value of Tests; D040901:Proteomics / Q000379:methods; D012074:Remission Induction; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D005819:Genetic Markers
keywords: BIOMARKERS; INTEGRATIVE; MECHANISTIC; PATHWAYS; PSORIATIC ARTHRITIS